Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: David Lenigas answers investor questions in a detailed interview about UKOG, Doriemus, LGC Capital, AfriAg and Angus Energy.


Glaxosmithkline Share Price (GSK)



Share Price Information for Glaxosmithkline (GSK)


Share Price: 1,523.50Bid: 1,523.00Ask: 1,523.50Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.50Spread as %: 0.03%Open: 1,543.00High: 1,544.00Low: 1,517.50Yesterday’s Close: 1,523.50

Glaxosmithkline Plc Ord 25P

Glaxosmithkline is listed in the FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Glaxosmithkline is part of the Medicine and Biotech Research sector

Glaxosmithkline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.





Share Price SpacerPrice
1523.50

Share Price SpacerBid
1523.00

Share Price SpacerAsk
1523.50

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
8,361,621

Share Price SpacerOpen
1,543.00

Share Price SpacerHigh
1,544.00

Share Price SpacerLow
1,517.50

Share Price SpacerClose
1,523.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 4,917.43m £74,917.08m 1,500

52 Week High 1,724.50 52 Week High Date 22-JUN-2017
52 Week Low 1,444.00 52 Week Low Date 19-SEP-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
8,742 3,209,430 4,997,855 81.037 18.80 80.00 5.25


London South East Users info for Glaxosmithkline


Users who watch GSK also watch: BP, Lloyds, Vodafone, Tesco, Barclays, RBS, HSBC, National Grid, Astrazeneca, BT

Users who hold GSK also hold: Vodafone, BP, National Grid, Lloyds, Tesco, Royal Dutch Shell B, HSBC, Aviva, BT, Centrica


Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

20-Oct-17
17:09:40
1,522.9689
322
Sell* 
1,523.00
1,523.50
4,904
Trade Type:
Ordinary
Bargain conditions apply
NonProtected portfolio
Single protected transaction

20-Oct-17
17:09:40
1,522.9689
322
Sell* 
1,523.00
1,523.50
4,904
Trade Type:
Ordinary
Bargain conditions apply

20-Oct-17
17:08:49
1,520.0886
158
Sell* 
1,523.00
1,523.50
2,402
Trade Type:
Ordinary
Bargain conditions apply




View more Glaxosmithkline trades >>

Directors Deals for Glaxosmithkline (GSK)
Trade DateActionNotifierPriceCurrencyAmountHolding
13-Oct-17Buy Dividends
Trade Notifier Information for GlaxoSmithKline
Victoria Whyte held the position of Company Secretary at GlaxoSmithKline at the time of this trade.
 Victoria Whyte
1526.59GBX5510543
13-Oct-17Buy Dividends
Trade Notifier Information for GlaxoSmithKline
Victoria Whyte held the position of Company Secretary at GlaxoSmithKline at the time of this trade.
 Victoria Whyte
1526.59GBX40710543
13-Oct-17Buy Dividends
Trade Notifier Information for GlaxoSmithKline
Dominic Redfern held the position of Chief Strategy Officer at GlaxoSmithKline at the time of this trade.
 Dominic Redfern
1519.5GBX2384061
View more Glaxosmithkline directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
14 Oct '17Gerry557RE: Divi in1,516.00No Opinion
Yes, always nice to see them dripping in. Mine are sat there waiting for a home. Should be bigger next time around when the extra ones kick the next ex divi date.

Till then it might have to be off to the pot until I find something else to buy or more of these if it dips lower again
12 Oct '17GraylingDivi in1,524.00Hold
Nice fat divi payment in account today!
11 Oct '17scooter786RE: GSK v AZN - a report.1,515.50No Opinion
Thank you. I just bought in at 15.20 for the long term.
10 Oct '17TLWilliams.RE: GSK v AZN - a report.1,518.00Buy
Scooter786
AZN
After shares fell 15% on a single day following the Mystic setback, can the shares rally back to pre-trial highs?
Relative Strength Index indicator remains stubbornly stuck below 50, regularly seen as a bearishly
Directional indicators diverging
The majority of brokers are positive-leaning, while over 80% expect the price to rise from current value.

GSK
Having failed to overcome 4-year resistance in June, shares have fallen to key support at 1475p?
Stochastics have… Read More
10 Oct '17scooter786RE: GSK v AZN - a report.1,523.00No Opinion
Cannot load it ! Can you summarise ? Please
6 Oct '17TLWilliams.GSK v AZN - a report.1,527.50Buy
velindre. This might be worth a read, if you haven't read it already. ATB

https://www.investmentsuperstore.co.uk/wp-content/uploads/2017/09/GlaxoVsAstrazenecaAug17.pdf

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Glaxosmithkline (GSK) >>

Please login or register to post a message on Share Chat.





Glaxosmithkline Plc Ord 25P home pageWebsite: Glaxosmithkline Plc Ord 25P
Website Description: GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of August 2016 it had a market capitalisation of £81 billion the fourth largest on the London Stock Exchange



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.